Corrigendum to “Rondeau E, Scully M, Ariceta G, Barbour T, Cataland S, Heyne N, Miyakawa Y, Ortiz S, Swenson E, Vallee M, Yoon S-S, Kavanagh D and Haller H; on behalf of the 311 Study Group. The long-acting C5 inhibitor, Ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment.” Kidney Int.2020;97:1287–1296

Autor: Rondeau, Eric, Scully, Marie, Ariceta, Gema, Barbour, Tom, Cataland, Spero, Heyne, Nils, Miyakawa, Yoshitaka, Ortiz, Stephan, Swenson, Eugene, Vallee, Marc, Yoon, Sung-Soo, Kavanagh, David, Haller, Hermann, Babu, Sunil, Broeders, Nilufer, Lietar, Nicole, Brown, Fiona, Campbell, Philip, Campistol, Josep M., Blasco, Miquel, Chowdhury, Paramit, Kasimatis, Theo, Cirami, Lino, Caroti, Leonardo, Antognoli, Guilia, Delmas, Yahsou, Dobronravov, Vladimir, Gaeckler, Anja, Garrouste, Cyril, Greenwood, Gregory, Griffin, Siân, Huang, Chiu-Ching, Chen, I-Ru, Huang, Susan, Kim, Jin Seok, La Manna, Gaetano, Comai, Giorgia, Cappuccilli, Maria, Le Quintrec, Moglie, Jeantet, Guillaume, Fumie, Iino, Luque, Yosu, Menne, Jan, Morelle, Johan, Goffin, Eric, Muhlfeld, Anja, Nagaraj, Shashi, Arepally, Gowthami, Oh, Doyeun, Okumi, Masayoshi, Terente, Manuel Praga, Gutierréz, Elena, Rodriguez, Paola, Provot, Francois, Schönermarck, Ulf, Fischereder, Michael, Terrada, Natalia Ramos, Seitz-Polski, Barbara, Favre, Guillaume, Boyer-Suavet, Sonia, Vinogradova, Maria, Kirsanova, Tatiana, Wong, Edwin K.S.
Zdroj: Kidney International; May 2021, Vol. 99 Issue: 5 p1244-1244, 1p
Databáze: Supplemental Index